Global Diabetic Neuropathy Market

Diabetic Neuropathy Market Size, Share, Growth Analysis, By Disorder(Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy), By Distribution channel(Hospitals, Clinics, Retail Pharmacy, Online Pharmacy), By Drug Class(Anti-Depressants, Anti-Seizures, Opioid, Non-Steroidal Anti-Inflammatory), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35I2245 | Region: Global | Published Date: February, 2024
Pages: 165 | Tables: 94 | Figures: 76

Diabetic Neuropathy Market Regional Insights

In 2021, the greatest market for diabetic neuropathy is in North America. In order to counteract the degradation of generic pharmaceuticals, pharma companies continue to give fresh medications in the area. Due to a big incidence of chronic diseases such as diabetes, and an increasing senior generation, diabetic neuropathy treatment has become extremely popular, particularly in the United States.

With economies such as China demonstrating profitable growth, the Asia Pacific area is the fastest-growing market overall. According to studies published, India does have one of the highest proportions of type 2 diabetes in the globe and by 2030, 80 million Indians are expected to have the disease. Due to the region's large population of patients, poorly enforced regulatory environment, rising Research and Development investment, expansion of clinical studies, and federal funding for therapeutic strategies, pharma industries are now expanding there. As a result, the market is expected to experience significant regional growth.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Diabetic Neuropathy Market size was valued at USD 3626.38 million in 2019 and is poised to grow from USD 3876.6 million in 2023 to USD 7067.25 million by 2031, growing at a CAGR of 6.9% in the forecast period (2024-2031).

Due to the rise in R&D projects, Johnson & Johnson and GlaxoSmithKline plc are the major players outperforming the diabetic neuropathy market. Major market companies are being influenced by this to diversify their product offerings globally. As a result, the important companies' varied product portfolios tend to increase the company's value. For instance, The most significant player in the market is thought to be Pfizer Inc. due to its emphasis on creating goods like Motrin and Lyrica that are expected to fuel growth. 'Johnson & Johnson ', 'Pfizer Inc ', 'Eli Lilly and Company', 'Boehringer Ingelheim International GmbH', 'GlaxoSmithKline plc', 'Astellas Pharma Inc.', 'Novartis AG', 'Sanofi S.A.', 'Teva Pharmaceutical Industries Ltd.', 'Merck & Co., Inc.', 'AbbVie Inc.', 'Glenmark Pharmaceuticals Limited', 'Lupin Pharmaceuticals, Inc.', 'Intas Pharmaceuticals Ltd.', 'Alkem Laboratories Ltd.', 'Cipla Limited', 'Mylan N.V.', 'Zydus Cadila Healthcare Limited', 'Sun Pharmaceutical Industries Ltd.', 'Dr. Reddy's Laboratories Ltd.'

Rise in prevalence of diabetes to cause a rise in the demand for diabetic neuropathy.

During the forecast year, high-tech goods will be developed for better diabetic neuropathy therapy. Companies are concentrating on creating transdermal patches, mouthwash, talc, as well as other products.  Manufacturers have introduced cutting-edge medication delivery systems, like syringe-free injection equipment, to combat problems related to surgical pharmaceuticals. As a result, NFIT has attracted significant interest in the treatment of the disease, which is helping the market expand. As a result, the market is expanding due to the rising demand for new drug delivery methods such as oral, transdermal, parenteral, and inhalation.

In 2021, the greatest market for diabetic neuropathy is in North America. In order to counteract the degradation of generic pharmaceuticals, pharma companies continue to give fresh medications in the area. Due to a big incidence of chronic diseases such as diabetes, and an increasing senior generation, diabetic neuropathy treatment has become extremely popular, particularly in the United States.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Diabetic Neuropathy Market

Report ID: SQMIG35I2245

$5,300
BUY NOW GET FREE SAMPLE